Stocks
G1 Therapeutics Financial Statements (GTHX) |
||||||||||
| G1 Therapeuticssmart-lab.ru | % | 2023Q1 | 2023Q2 | 2023Q3 | 2023Q4 | 2024Q1 | LTM ? | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Report date | 03.05.2023 | 02.08.2023 | 01.11.2023 | 28.02.2024 | 01.05.2024 | 01.05.2024 | ||||
| Currency | USD | USD | USD | USD | USD | USD | ||||
| Financial report URL | ||||||||||
| Revenue, bln rub | ? | 12.9 | 42.4 | 12.3 | 14.9 | 14.5 | 84.0 | |||
| Operating Income, bln rub | -25.7 | 11.5 | -16.4 | -8.93 | -9.05 | -22.8 | ||||
| EBITDA, bln rub | ? | -24.5 | 12.9 | -16.4 | -8.81 | -8.93 | -21.2 | |||
| Net profit, bln rub | ? | -32.5 | 8.71 | -18.2 | -10.9 | -10.2 | -30.6 | |||
| OCF, bln rub | ? | -29.1 | 14.1 | -10.6 | -12.8 | -8.90 | -18.2 | |||
| CAPEX, bln rub | ? | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |||
| FCF, bln rub | ? | -29.1 | 14.1 | -10.6 | -12.8 | -8.90 | -18.2 | |||
| Dividend payout, bln rub | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | ||||
| Ordinary share dividend yield, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | ||||
| Dividend payout ratio, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0 | ||||
| OPEX, bln rub | 37.2 | 29.5 | 28.7 | 22.5 | 22.4 | 103.1 | ||||
| Cost of production, bln rub | 1.46 | 1.40 | 3.08 | 1.26 | 1.08 | 6.82 | ||||
| R&D, bln rub | 15.5 | 12.0 | 8.81 | 7.38 | 7.32 | 35.5 | ||||
| Interest expenses, bln rub | 3.09 | 2.71 | 2.12 | 2.12 | 1.98 | 8.93 | ||||
| Assets, bln rub | 162.0 | 147.9 | 133.1 | 121.5 | 102.0 | 102.0 | ||||
| Net Assets, bln rub | ? | -759.6 | 57.5 | -769.1 | 35.4 | 27.7 | 27.7 | |||
| Debt, bln rub | 5.31 | 55.9 | 4.68 | 57.2 | 47.1 | 47.1 | ||||
| Cash, bln rub | 116.3 | 104.2 | 94.4 | 82.2 | 65.2 | 65.2 | ||||
| Net debt, bln rub | -111.0 | -48.3 | -89.7 | -25.0 | -18.2 | -18.2 | ||||
| Ordinary share price, rub | 2.68 | 2.49 | 1.44 | 3.05 | 4.32 | 1.61 | ||||
| Number of ordinary shares, mln | 51.6 | 51.7 | 51.8 | 51.8 | 52.2 | 52.2 | ||||
| Market cap, bln rub | 138 | 129 | 75 | 158 | 225 | 84 | ||||
| EV, bln rub | ? | 27 | 80 | -15 | 133 | 207 | 66 | |||
| Book value, bln rub | -760 | 58 | -769 | 35 | 28 | 28 | ||||
| EPS, rub | ? | -0.63 | 0.17 | -0.35 | -0.21 | -0.20 | -0.59 | |||
| FCF/share, rub | -0.56 | 0.27 | -0.20 | -0.25 | -0.17 | -0.35 | ||||
| BV/share, rub | -14.7 | 1.11 | -14.9 | 0.68 | 0.53 | 0.53 | ||||
| EBITDA margin, % | ? | -189.3% | 30.3% | -133.1% | -59.2% | -61.7% | -25.3% | |||
| Net margin, % | ? | -251.3% | 20.5% | -148.0% | -73.1% | -70.6% | -36.4% | |||
| FCF yield, % | ? | -86.7% | -52.0% | -75.3% | -24.2% | -8.07% | -21.6% | |||
| ROE, % | ? | 17.6% | -143.8% | 9.84% | -149.5% | -110.3% | -110.3% | |||
| ROA, % | ? | -82.4% | -55.9% | -56.9% | -43.5% | -30.0% | -30.0% | |||
| P/E | ? | -1.04 | -1.55 | -0.99 | -2.99 | -7.37 | -2.75 | |||
| P/FCF | -1.15 | -1.92 | -1.33 | -4.12 | -12.4 | -4.62 | ||||
| P/S | ? | 2.41 | 1.44 | 0.96 | 1.92 | 2.68 | 1.00 | |||
| P/BV | ? | -0.18 | 2.24 | -0.10 | 4.47 | 8.13 | 3.03 | |||
| EV/EBITDA | ? | -0.24 | -1.28 | 0.26 | -3.61 | -9.75 | -3.10 | |||
| Debt/EBITDA | 0.99 | 0.77 | 1.54 | 0.68 | 0.85 | 0.85 | ||||
| CAPEX/Revenue, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0 | ||||
| G1 Therapeutics shareholders | ||||||||||
